Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced results from a 24-week open-label study demonstrating that treatment with Contrave(R) resulted in significant improvements in depressive symptoms that was accompanied by weight loss and improved control of eating in overweight and obese patients with major depression.
Mason, OH – July 1, 2010– “This study is the first step in assessing the value of Contrave in this important patient population and these positive results should encourage additional investigation,” said Susan McElroy, MD, Lindner Center of HOPE.
About the Lindner Center of HOPE:
Lindner Center of HOPE provides patient-centered, scientifically-advanced care for individuals suffering with mental illness. A state-of-the-science, free-standing mental health center, Lindner Center of HOPE is a charter member of the National Network of Depression Centers. The Center provides psychiatric hospitalization for individuals age 11-years-old and older, outpatient services for all ages, research, voluntary live-in services, partial hospitalization programs, Transcranial Magnetic Stimulation (TMS), diagnostic imaging and first-class amenities to patients suffering from mood disorders, anxiety disorders, schizophrenia and related illnesses, eating and weight disorders, ADHD and substance use conditions. The Center employs a stellar multidisciplinary team that utilizes years of experience and evidence-based treatments to partner with patients and families to reach positive outcomes. The Lindner Center of HOPE is affiliated with the University of Cincinnati (UC) College of Medicine. The Center, which began serving patients and families on August 18, 2008, is a non-profit mental health care provider located in Mason, Ohio.
Lindner Center of HOPE